Hugely expensive drugs QUACKERY

PHARMA industry can be accused of quackery!!
Die pharmaindustrtie koennte der Quacksalberei beschuldigt werden:

---

Afinitor is supplied as a 5 mg or 10 mg tablet
inhibitor of mTOR (mammalian target of rapamycin)
http://en.wikipedia.org/wiki/Everolimus
mTOR Novartis Everolimus Zortress USA Certican EUROPE
Certican 0,75 mg - Tabletten - 100 ST 1058 EURO

---

http://en.wikipedia.org/wiki/Pazopanib
GSK erhält eingeschränkte EU-Zulassung für Krebsmittel "Votrient"15.06.2010

---

TORISEL 25mg/ml Infusionslösungskonzentrat
(temsirolimus; Wyeth) 1.159,43 EURO

---

Sutent (Sunitinib) 25mg Kapseln Inhalt: 28 Stück
3.277,52 Euro
Sutent 50mg 30 Stück 7.254,59 euro
Sunitinib malat 66.83 mg
Hersteller des Arzneimittels: Pfizer Pharma GmbH Linkstrasse, 10785 Berlin Tel: 030/55005551010

---

NEXAVAR (Sorafenib Bexavarm) 200mg (112 Stück)
Bayer Schering/Onyx Pharmaceuticals
Preis: 4.914,89 Euro, PZN: 6639677

---

AVASTIN - (Bevacizumab) intravenously
every 14 days. Roche Pharma Genentech
single use: 1723 euro

---

---

Clinical Trials, Phase II:

- Aflibercept (1)
- Axitinib (1) (2) (3)
- Desatinib
- Ixabepilone (1)
- Vandetanib (1)
- Vorinostat (1) (2)
Clinical Trials, Phase I:

- Vatalanib (1)
- Yttrium-90 conjugated chimeric G250 (90Y-cG250)

---

---

Sutent and Avastin

In a poster session, Darren Feldman reported on a current Phase 1 trial of the combined therapies, Avastin and Sutent, at a single institution, Memorial Sloan-Kettering (MSKCC). The theory behind combining these two therapies is that while Sutent is an inhibitor of the vascular endothelial growth factor receptor (VEGFR), a promoter of angiogenesis, it also increases VEGF itself. Avastin blocks VEGF so the combination would theoretically have a longer lasting effect. This trial is similar to the one presented at last year's ASCO conference by Jeffrey Sosman of Vanbderbilt University in which the combination of Nexavar and Avastin was used. In that trial, dose limiting toxicities prevented investigators from reaching the standard dosage for Nexavar of 800 mg per day, which impacted the response rate.

The Phase 1 trial was divided into three cohorts, each receiving the fixed dose of Avastin of 10 mg/kg but each cohort receiving escalating doses of Sutent: 25 mg, 37.5 mg, and 50 mg daily, 4 weeks on, 2 weeks off. This was a small trial with cohorts of 3-6 patients. The third cohort received the standard dose of Sutent of 50 mg daily.

19 patients in total entered the study with six having entered the 2nd dose level and six the 3rd level. Six patients were at 50 mg of Sutent for only one cycle. Grade 3/4 toxicities included hypertension (8 pts), elevated lipase (7 pts), and hand-foot syndrome (3 pts). In addition, there were two grade 4 dose-limiting toxicities of hemorrhaging.

Sutent and Avastin Response



Patients (%)

Partial Response


7(37%)

Stable Disease


10(53%)

Progressive Disease


2(11%)

Feldman concluded that 10 mg/kg of Avastin and 50 mg of Sutent is "tolerable and safe" in RCC patients, but 42% grade 3/4 hypertension is significant especially compared to the 8% figure for Sutent alone as presented at ASCO 2007 by Motzer in his updated results of Sutent versus Interferon. On the other hand, these are still preliminary data as the trial has not yet matured. MSKCC is planning a randomized placebo-controlled Phase 2 trial of Avastin at 10 mg/kg and Sutent at 50 mg daily.



Mission Statement

ACKC is a grassroots organization established in 2003 by kidney cancer patients and their families/caregivers who are working to raise awareness of kidney cancer and to ensure that it receives the public and private funding required to identify and develop effective treatment modalities and to find a cure for this disease. ACKC works with government officials, research institutions, and other interested organizations and individuals to increase the level of funding for kidney cancer research.
GOALS:

The goals of ACKC are to:

1. Educate government officials, kidney cancer patients and caregivers, and the general public about kidney cancer.
2. Advocate for the increase in government and private sector funding for research to find the causes, diagnostic and treatment options, and ultimately a cure for kidney cancer.
3. Expand our national network of grassroots supporters to join with us in our advocacy efforts.
4. Provide funding for kidney cancer research projects.
5. Support the work of physicians, scientists, and other researchers working in the kidney cancer field.
6. Cooperate with other organizations in order to achieve mutual goals.